Formycon Ag · XETR:FYB
Formycon — Investor Presentation (May 2025)
19 slides from Formycon's investor presentation, May 2025
Slide 1: The Biosimilar Experts
The Biosimilar Experts May 2025
Slide 2: Disclaimer
Disclaimer This presentation may contain forward-looking statements and information which are based on our current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial si
Slide 3: Contributing to ease the financial strains on the world's healthcare systems
Contributing to ease Improving the financial strains on the patient access to vital world’s healthcare systems medicines
Slide 4: Skillset and mindset are our key ingredients
Skillset and mindset are our key ingredients < formycon Pure Play Biosimilar Company - established 2012 in Munich, Germany. Business model contains Income from success payments and royalty streams. (a? 250 employees from more than 30 different countries. More than 80% of Formycon’s workforce is enga
Slide 5: Number of blockbuster drugs losing exclusivity
Year Number of blockbuster drugs losing exclusivity Cumulative global annual peak sales in USD bn
Slide 6: Biosimilars is the fastest growing segment in Pharma
Biosimilars is the fastest growing segment in Pharma. The US market has seen the fastest growth in Biosimilars with a CAGR of 97 % from 2015 – 2021. Although projections to 2025 show a lower rate of growth, the United States is expected to stay in pole position.
Slide 7: Maximizing our assets along a clear path
Maximizing our assets along a clear path 2024 2025
Slide 8: Key global markets
US* ex-US MENA Brasilien Key global Markets MENA Europe MENA APAC (major Parts)
Slide 9: Strong first Quarter of 2025 — many important operational Milestones achieved
Strong first Quarter of 2025 — many important operational Milestones achieved < formycon g © Approval of Approval of Stelara® Biosimilar Stelara® Biosimilar FYB202/Otulfi® in FYB202/Otulfi® in Canada UK Commercialization Commercialization Partnership with Teva Partnership with Lotus for Eylea® Biosi
Slide 10: Growth drivers: Lucentis Biosimilar FYB201
Lucentis® Biosimilar FYB201 — Strong Presence across the World FYB201/ranibizumab so far launched in 20 Countries omer) 0 Formycon AG // The Biosimilar Experts ww Ongavia \Ranivisio < formycon Growth drivers © Introduction of Prefilled Syringe in European Markets Entering additional Markets globally
Slide 11: Growth drivers: Formycon Income Position
Growth drivers Formycon Income Position
Slide 12: Growth drivers: Eylea Biosimilar FYB203
Eylea® Biosimilar FYB203 — @¥ormycon approved in US, EU and UK FYB203/aflibercept waiting in the wings Growth drivers Commercial Partnerships A @ _ International Approvals Preparing Supply Chain in Accordance with IP Landscape ® F78203 approved MSpharma Fylea® I a registered trademark of Regeneron P
Slide 13: FYB206 - Keytruda Biosimilar Candidate
FYB206 - Keytruda® Biosimilar Candidate @¥ormycon in the leading group Targeted Reference Indications Achievements and next important Milestones Immuno-oncology: Melanoma (black skin cancer), @ Clinical Phase | trial “Dahlia” started in June 2024 investigating non-small cell Lung Cancer, classical H
Slide 14: Outlook for 2025 — further significant commercial and operational milestones in sight
Outlook for 2025 — further significant < formycon commercial and operational milestones in sight Approval of Approval and Launch Commercial Launch Commercial Launch Commercialization Lucentis® Biosimilar of prefilled Syringe for of Stelara® Biosimilar of Stelara® Biosimilar Partnerships for Eylea® F
Slide 15: 2025 outlook — Guidance confirmed
®¥ormycon 2025 outlook — Guidance confirmed Guidance ; Guidance 2025 Adjusted Working 2025 Revenue EBITDA ee Capital 55 t0 65 -20 to -10 -20 to -10 25 10 35 Gos @ 1Q revenue as expected € million € million € million € million EBITDA: © For Full Year expected on guidance Key financial v EBITDA Adjust
Slide 16: Analyst ratings
− − − − − − − Buy − Buy − Buy − Buy − ~ − Buy − Buy − − Buy − Neutral − Buy − Buy − Buy
Slide 17: Fully focused Pure-Play Biosimilar Company
Fully focused Pure-Play < formycon Biosimilar Company & @ WE HAVE all ingredients to WE ACT in a highly WE CREATED WE ARE entering the next successfully develop and attractive market a strong Platform with stage of the Formycon commercialize a growing track record Growth Story pipeline 17 Formycon A
Slide 18: I am happy to answer your questions
< formycon Formycon AG | AM HAPPY TO ANSWER YOUR QUESTIONS www.formycon.com x X 18 Formycon AG // The Biosimilar Experts
Slide 19: Formycon AG contact details
< formycon Formycon AG Formycon AG Fraunhoferstr. 15 82152 Planegg-Martinsried Germany + 49 89 864 667 100 info@formycon.com www.formycon.com m xX X 19 Formycon AG // The Biosimilar Experts